EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSMMDG00005009476
Gene Symbol: CACNA1A
1 Cross references
186 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSMMDG00005015724
Gene Symbol: CACNA1B
1 Cross references
218 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSMMDG00005006462
Gene Symbol: CACNA1D
1 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSMMDG00005003763
Gene Symbol: CACNA1E
1 Cross references
215 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSMMDG00005003007
Gene Symbol: CNR1
1 Cross references
134 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSMMDG00005017212
Gene Symbol: CNR1
1 Cross references
150 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSMMDG00005017851
Gene Symbol: CNR2
1 Cross references
191 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSMMDG00005011332
Gene Symbol: CA12
1 Cross references
214 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSMMDG00005001328
Gene Symbol: LOC115369744
3 Cross references
196 Possible Orthologues:

Carbonic Anhydrase 5b, Mitochondrial-Like

Ensembl ID : ENSMMDG00005011737
Gene Symbol: LOC115361168
3 Cross references
231 Possible Orthologues:

Carbonic Anhydrase 6

Ensembl ID : ENSMMDG00005000738
Gene Symbol: CA6
1 Cross references
215 Possible Orthologues:

Carbonic Anhydrase 7

Ensembl ID : ENSMMDG00005003344
Gene Symbol: CA7
3 Cross references
221 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).